CytomX (NASDAQ: CTMX) CFO gets 325,000 options and 90,000 RSUs in equity grant

Rhea-AI Filing Summary

CytomX Therapeutics reported new equity awards for its Chief Financial Officer, Christopher Ogden. On February 2, 2026, he acquired a stock option covering 325,000 shares of common stock at an exercise price of $6.09 per share and a grant of 90,000 restricted stock units (RSUs) at no cost.

The option vests in equal monthly installments over four years starting from February 2, 2026, becoming fully vested on the fourth anniversary, subject to continued service. The RSUs vest in three equal annual installments each March 15, beginning March 15, 2027, also subject to his continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Ogden Christopher

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	325,000	$0.00	--
Grant/Award	Common Stock	90,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 325,000 shares (Direct); Common Stock — 316,271 shares (Direct)

Footnotes (1)

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date. Includes 239,987 RSUs. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ogden Christopher

(Last) (First) (Middle)

C/O CYTOMX THERAPEUTICS, INC.

151 OYSTER POINT BLVD., SUITE 400

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CytomX Therapeutics, Inc. [ CTMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		A		90,000(1)	A	$0	316,271(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.09	02/02/2026		A		325,000		(3)	02/01/2036	Common Stock	325,000	$0	325,000	D

Explanation of Responses:

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date.

2. Includes 239,987 RSUs.

3. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

	/s/ Christopher Ogden	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CTMX CFO Christopher Ogden report?

Christopher Ogden reported receiving a stock option for 325,000 shares and 90,000 RSUs in CytomX Therapeutics common stock. Both awards were granted at no cash cost to him and are tied to future service-based vesting schedules over multi-year periods.

How many CytomX (CTMX) stock options were granted to the CFO?

The CFO received a stock option covering 325,000 shares of CytomX common stock at an exercise price of $6.09 per share. The option vests monthly over four years from February 2, 2026, becoming fully vested on the fourth anniversary, contingent on continued service.

What are the terms of the 90,000 RSUs granted to CTMX’s CFO?

The 90,000 RSUs entitle the CFO to one share of CytomX common stock per unit upon vesting. One-third vests each March 15, starting March 15, 2027, with vesting conditioned on his continued status as a service provider through each vesting date.

What is the vesting schedule for Christopher Ogden’s CTMX stock options?

One forty-eighth of the 325,000-share option vests on each monthly anniversary of February 2, 2026. The option becomes fully vested and exercisable on the fourth anniversary of that date, assuming Mr. Ogden continues providing service to CytomX throughout the vesting period.

How many CTMX shares does the CFO beneficially own after this Form 4?

Following the reported transactions, the CFO beneficially owns 316,271 shares of CytomX common stock, including 239,987 RSUs. This figure reflects his direct ownership position after the new 90,000 RSU grant reported in the filing on February 2, 2026.

Did the CTMX CFO pay cash for the newly reported equity awards?

The filing shows both the 325,000-share stock option grant and the 90,000 RSU grant at a transaction price of $0 per unit. While the option has a $6.09 exercise price, no cash was paid at grant; value depends on future vesting and potential exercise.